| Robert Lp Knight, DO | |
|
3960 Brown Park Dr Ste A, Hilliard, OH 43026-1161 | |
| (614) 642-4012 | |
| (614) 675-7181 |
| Full Name | Robert Lp Knight |
|---|---|
| Gender | Male |
| Speciality | Neuromusculoskeletal Medicine & Omm |
| Location | 3960 Brown Park Dr Ste A, Hilliard, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235699299 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 34.015518 (Ohio) | Secondary |
| 204D00000X | Neuromusculoskeletal Medicine & Omm | 34.015518 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Robert Lp Knight, DO 3960 Brown Park Dr Ste A, Hilliard, OH 43026-1161 Ph: (614) 642-4012 | Robert Lp Knight, DO 3960 Brown Park Dr Ste A, Hilliard, OH 43026-1161 Ph: (614) 642-4012 |
News Archive
The Medical University of Vienna is coordinating an international research project, which investigates the effectiveness of tried and tested medicines for the treatment of some of the heaviest burdens of our modern society including diseases such as cancer, diabetes and cardiovascular diseases. One molecule that these disorders have in common is a receptor known as the calcium-sensing receptor (CaSR), which is the molecular starting point of this project.
A team of Vermont investigators has been issued a patent for their discovery of a molecule that rescues damaged blood vessels, yet preserves healthy vessels and could serve as a springboard for a new pharmaceutical therapy with fewer side effects for hypertension - a major risk factor for cardiovascular and kidney disease that effects roughly one in three people in the U.S.
Amylin Pharmaceuticals, Inc. today announced results from new analyses of previously completed clinical studies demonstrating that patients with type 2 or type 1 diabetes achieved a greater proportion of blood glucose measurements in the normal range when SYMLIN (pramlintide acetate) injection treatment was used along with insulin.
Celgene Corporation today announced the successful pricing of three series of senior unsecured notes for an aggregate principal amount of $1.25 billion.
Advance directives (ADs) are legal documents you can use to state in advance what medical treatments you do or do not wish to have under certain circumstances.
› Verified 8 days ago